[Serum level of sL-selectin and leukocyte surface expression of L-selectin in patients with type 2 diabetes].
The aims of the study were assessment of serum level of sL-selectin and leukocyte (neutrophil and monocyte) surface expression of L-selectin in peripheral blood. Subjects and methods. Eighty patients with type 2 diabetes were enrolled in the study. The diabetic patients were divided into three groups: group A--diabetic micro-angiopathy, group B--diabetic macroangiopathy and group C--patients without vascular complications. The control group included 20 healthy volunteers. Serum level of sL-selectin was determined by immunoenzymatic assay. Flow cytometry was used to analyse surface expresion of L-selectin. Results. In patients with type 2 diabetes sL-selectin level was significantly decreased in comparison with control group. Serum level of sL-selectin did not significantly vary between diabetic groups. In patients with diabetic microangiopathy and macroangiopathy leukocyte expression of L-selectin was significantly lower in comparison with the healthy control and patients without vascular complications. Serum level of sL-selectin is decreased in patients with type 2 diabetes. The development of chronic vascular complications, diabetic micro- and macroangiopathy, is accompanied by decrease of leukocyte surface expression of L-selectin.